Synthesis, molecular docking, and antiproliferative activity studies of bromine bearing Schiff bases

ArticleAçık Erişim

Özet

Bromine-bearing compounds are found in a variety of natural products and synthetic drugs and exhibit a variety of biological activities. They often display particular properties such as enhanced stability, improved lipophilicity, and larger molecular interactions, making them valuable in drug design and development. In this study, three bromine-bearing Schiff bases were synthesized, characterized, and tested in lung (A549) and colon (DLD-1) cancer cell lines for 72 h incubation time. The results demonstrated that compounds had antiproliferative activity in screened cell lines. The compounds were also tested on a healthy embryonic kidney cell line (HEK-293T) to evaluate their toxic effects on non-cancerous cells. In vitro results of compounds interacting with the most suitable target were confirmed by in silico approaches. All bromine-containing compounds were interacted with the receptor tyrosine kinase FLT3 target via molecular docking. From the interaction results of the 6JQR crystal structure with 2-Br, the docking score value was calculated as −8.178 kcal/mol, and this value was determined to be better than the docking score (−7.269 kcal/mol) value of gilteritinib. Pharmacokinetics, toxicity properties and Lipinski violations of the compounds were estimated by ADMET and were calculated to be in the range of recommended values. Molecules demonstrated limited efficacy against A549 cells line, however; they exhibited relatively greater effectiveness against DLD-1 cell line. Notably, the IC50 value of 2-Br was comparable to that of cisplatin. All molecules exhibited minimal toxicity. © 2025 Elsevier Inc.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10969Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1016/j.bbrc.2025.151739Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKaratas, Halis
dc.contributor.authorTurkmenoglu, Burçin
dc.contributor.authorKokbudak, Zülbiye
dc.contributor.authorAkkoc, Senem
dc.date.accessioned2026-10-18T20:26:04.864916424Z
dc.date.available2026-10-18T20:26:04.864916424Z
dc.date.issued2025
dc.description.abstractBromine-bearing compounds are found in a variety of natural products and synthetic drugs and exhibit a variety of biological activities. They often display particular properties such as enhanced stability, improved lipophilicity, and larger molecular interactions, making them valuable in drug design and development. In this study, three bromine-bearing Schiff bases were synthesized, characterized, and tested in lung (A549) and colon (DLD-1) cancer cell lines for 72 h incubation time. The results demonstrated that compounds had antiproliferative activity in screened cell lines. The compounds were also tested on a healthy embryonic kidney cell line (HEK-293T) to evaluate their toxic effects on non-cancerous cells. In vitro results of compounds interacting with the most suitable target were confirmed by in silico approaches. All bromine-containing compounds were interacted with the receptor tyrosine kinase FLT3 target via molecular docking. From the interaction results of the 6JQR crystal structure with 2-Br, the docking score value was calculated as −8.178 kcal/mol, and this value was determined to be better than the docking score (−7.269 kcal/mol) value of gilteritinib. Pharmacokinetics, toxicity properties and Lipinski violations of the compounds were estimated by ADMET and were calculated to be in the range of recommended values. Molecules demonstrated limited efficacy against A549 cells line, however; they exhibited relatively greater effectiveness against DLD-1 cell line. Notably, the IC50 value of 2-Br was comparable to that of cisplatin. All molecules exhibited minimal toxicity. © 2025 Elsevier Inc.
dc.description.sponsorshipSA gratefully acknowledges the financial support from the S\u00FCleyman Demirel University Research Fund under project number TSG-2024-9516.
dc.identifier.doi10.1016/j.bbrc.2025.151739
dc.identifier.eissn1090-2104
dc.identifier.issn0006-291X
dc.identifier.pmid40179736
dc.identifier.scopus2-s2.0-105001544504
dc.identifier.startpage151739
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10969
dc.identifier.volume761
dc.identifier.wosWOS:001463159300001
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofBiochemical and Biophysical Research Communications
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectADMET
dc.subjectAntiproliferative activity
dc.subjectBromine
dc.subjectMolecular docking
dc.subjectSchiff base
dc.subjectA549 Cells
dc.subjectAntineoplastic Agents
dc.subjectCell Line, Tumor
dc.subjectCell Proliferation
dc.subjectHEK293 Cells
dc.subjectHumans
dc.subjectMolecular Docking Simulation
dc.subjectSchiff Bases
dc.subject(e) 1 ((2 bromobenzylidene)amino) 5 (4 methoxybenzoyl) 4 (4 methoxyphenyl)pyrimidin 2(1h) one (2 br)
dc.subject(e) 1 ((3 bromobenzylidene)amino) 5 (4 methoxybenzoyl) 4 (4 methoxyphenyl)pyrimidin 2(1h) one (3 br)
dc.subject(e) 1 ((4 bromobenzylidene)amino) 5 (4 methoxybenzoyl) 4 (4 methoxyphenyl)pyrimidin 2(1h) one (4 br)
dc.subjectgilteritinib
dc.subjectunclassified drug
dc.subjectantineoplastic agent
dc.subjectadmet study
dc.subjectArticle
dc.subjectbinding site
dc.subjectcarbon nuclear magnetic resonance
dc.subjectcell viability
dc.subjectchemical structure
dc.subjectcontrolled study
dc.subjectcrystal structure
dc.subjectcytotoxicity
dc.subjectdensity functional theory
dc.subjectdrug synthesis
dc.titleSynthesis, molecular docking, and antiproliferative activity studies of bromine bearing Schiff bases
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus6
rdl.citation.wos6
rdl.departmentErzincan Binali Yıldırım University, Faculty of Pharmacy, Department of Analytical Chemistry, Erzincan, 24002, Türkiye.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)